US Patent

US11564926 — Methods of synthesizing thyroid hormone analogs and polymorphs thereof

Method of Use · Assigned to Hoffmann La Roche Inc · Expires 2033-09-17 · 7y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of synthesizing pyridazinone compounds, including thyroid hormone analogs and their prodrugs, and their polymorphs.

USPTO Abstract

The disclosure describes methods of synthesis of pyridazinone compounds as thyroid hormone analogs and their prodrugs. Preferred methods according to the disclosure allow for large-scale preparation of pyridazinone compounds having high purity. In some embodiments, preferred methods according to the disclosure also allow for the preparation of pyridazinone compounds in better yield than previously used methods for preparing such compounds. Also disclosed are morphic forms of a pyridazinone compound. Further disclosed is a method for treating resistance to thyroid hormone in a subject having at least one TRβ mutation.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3861 resmetirom
U-3861 resmetirom
U-3861 resmetirom

Patent Metadata

Patent number
US11564926
Jurisdiction
US
Classification
Method of Use
Expires
2033-09-17
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Hoffmann La Roche Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.